Compounds > ly 353381
Page last updated: 2024-09-05

ly 353381 and enzastaurin

ly 353381 has been researched along with enzastaurin in 1 studies

Compound Research Comparison

Studies
(ly 353381)		Trials
(ly 353381)		Recent Studies (post-2010)
(ly 353381)		Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010) (enzastaurin)
7012151885299

Protein Interaction Comparison

ProteinTaxonomyly 353381 (IC50)enzastaurin (IC50)
Protein kinase C gamma typeHomo sapiens (human)0.7915
Protein kinase C alpha typeRattus norvegicus (Norway rat)0.7
Protein kinase C beta typeHomo sapiens (human)0.1797
Protein kinase C delta typeRattus norvegicus (Norway rat)0.7
Protein kinase C epsilon typeRattus norvegicus (Norway rat)0.7
Protein kinase C zeta typeRattus norvegicus (Norway rat)0.7
Protein kinase C alpha typeHomo sapiens (human)0.4695
Protein kinase C eta typeHomo sapiens (human)0.4
Protein kinase C gamma typeRattus norvegicus (Norway rat)0.7
Protein kinase C beta typeRattus norvegicus (Norway rat)0.7
Protein kinase C epsilon typeHomo sapiens (human)0.38
Protein kinase C zeta typeHomo sapiens (human)8
Protein kinase C delta typeHomo sapiens (human)1
Calcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)10
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)10
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)10
Protein kinase C eta typeRattus norvegicus (Norway rat)0.7
Calcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)10
Protein kinase C theta typeRattus norvegicus (Norway rat)0.7

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dotterer, SK; Forbes, RA; Hammill, CL1

Other Studies

1 other study(ies) available for ly 353381 and enzastaurin

ArticleYear
Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation.
    Journal of pharmaceutical and biomedical analysis, 2011, Apr-05, Volume: 54, Issue:5

    Topics: Chromatography, High Pressure Liquid; Copper; Drug Contamination; Drug Stability; Indoles; Iron; Molecular Structure; Pharmaceutical Preparations; Piperidines; Solutions; Solvents; Spectrophotometry, Atomic; Thiophenes

2011